The efficacy of NPB in combination with cisplatin29 and PARP inhibitors in ovarian carcinoma (OC)30 and in PTEN-deficient endometrial carcinoma (EC)31 were also recently reported. This evidence concerns the gene PTEN and ovarian carcinoma.